Transcode Therapeutics (RNAZ) Establishes $14 Million Standby Equity Purchase Agreement with Yorkville
Transcode Therapeutics, Inc. (RNAZ) announced on April 6, 2026, the establishment of a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD, providing the company with access to up to $14 million in equity financing. This agreement allows RNAZ, at its sole discretion, to sell shares of its common stock to Yorkville at a price set at 97% of the lowest daily volume-weighted average price (VWAP) over a three-day period. This flexible financing facility offers RNAZ a potential source of capital to support its operations and development initiatives, without an immediate obligation to draw funds. While providing financial flexibility, the agreement also signals potential future dilution for existing shareholders as the company may issue new shares.
Key Highlights
- Transcode Therapeutics (RNAZ) entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD (Yorkville) on April 6, 2026.
- The SEPA grants RNAZ the right to sell up to $14 million of its common stock to Yorkville over the term of the agreement.
- Sales of common stock under the SEPA are at the Company's sole option, with no obligation to sell any shares.
- The purchase price per share for each advance will be 97% of the lowest daily Volume Weighted Average Price (VWAP) during a three-consecutive-trading-day pricing period.
- Key conditions for Yorkville's purchase obligation include the effectiveness of a registration statement for resale and no outstanding balance under certain Convertible Notes.
Price Impact
More from RNAZ
More in Equity Offering
One & one Green Technologies Secures $13M in Follow-on Offering from Institutional Investors, with Option for Additional $3M
Linkers Industries Completes Full Exercise of Series B Cashless Warrants, Resulting in 1.52M Class A Shares Outstanding
Annovis Bio Secures $10M Public Offering, Extends Cash Runway to Q2 2027, Funds NDA Submission with AD Phase 3 Trial 75% Enrolled